SASKATOON, SK, Aug. 25, 2021 /CNW/ – Iotron Medical Inc. (Iotron) and Canadian Isotope Innovations Corp. (CIIC) are pleased to announce a collaboration to produce the radioisotope copper-67 (Cu-67) for new cancer therapies. This investment will increase the production capacity of the CIIC-operated facilities in Saskatoon, making Cu-67 more widely available to international cancer researchers. (read more)
New Radioisotope for Cancer Therapy – A new Collaboration to produce Copper-67
| Published: September 27, 2021
Health Canada Approves Cyclotron Produced Technetium-99m utilizing the ARTMS QIS™ and Solid Targets
| Published: September 27, 2021
BURNABY, British Columbia–(BUSINESS WIRE)–ARTMS Inc. (ARTMS) is excited to announce Health Canada’s marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use. For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the Centre for Probe Development and Commercialization. The process was approved by Health Canada on November 26, 2020 and is being deployed immediately. (read more)
Health Canada Approves Cyclotron Produced Technetium-99m utilizing the ARTMS QIS™ and Solid Targets
| Published: September 27, 2021
ARTMS Inc. (ARTMS) is excited to announce Health Canada’s marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use. For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the Centre for Probe Development and Commercialization. The process was approved by Health Canada on November 26, 2020 and is being deployed immediately. (read more)
Canadian firms make progress with radioisotope production
| Published: May 11, 2021
Researched and written by World Nuclear News – September 25, 2020
Ontario Power Generation (OPG), its subsidiary Laurentis Energy Partners, BWXT ITG Canada Inc and its affiliates yesterday said they are making “significant progress” towards the production of molybdenum-99 (Mo-99) at OPG’s Darlington plant. Darlington will be the first large-scale nuclear power station to produce the medical radioisotope, they said.
OPG announced in June 2018 that Darlington would produce Mo-99 for use in new technetium-99m (Tc-99m) generators designed by BWX Technologies Inc. Over the past 24 months, a team of more than 100 personnel at BWXT and Laurentis have designed specialised tooling to enable the production of Mo-99 at Darlington, and this is now being manufactured at BWXT’s facility in Peterborough, Ontario.
BWXT has also built a fabrication facility to produce Mo-99 components that will be delivered by the specialised tooling, which will be installed at Darlington. The tooling will deliver natural molybdenum into the Darlington reactor for irradiation, which will enable Darlington to become the first commercial operating nuclear reactor to produce Mo-99.
Mo-99 is used to generate Tc-99m, which is the world’s most widely used radionuclide for medical imaging. Both Tc-99m and the Mo-99 it is generated from have short half-lives and need to be used quickly once they are produced, so a constant, stable supply of them is needed. Mo-99 has primarily been produced by a limited number of research reactors, using enriched uranium targets.
“This advanced equipment is an example of how Laurentis is maximising decades of experience within the nuclear industry for the delivery of innovative solutions,” said Dominique Minière, president of Laurentis Energy Partners.
“We are well under way with the transformation of our nuclear medicine facility in Ottawa to be able to process Mo-99 and manufacture Tc-99m generators,” BWXT ITG President Martyn Coombs said. “These generators will be used to make radiopharmaceuticals for patients, and will help to resolve historical shortages of this vital product.”
OPG is in the process of refurbishing the four Candu reactors at the Darlington plant in a CAD12.8 billion (USD9 billion), 10-year project that will enable the station to operate for an additional 30 years. The first unit to undergo refurbishment – Darlington 2 – returned to service in June and work started on the refurbishment of unit 3 earlier this month.
Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production
HAMILTON, ON and BOSTON and VANCOUVER, BC, Aug. 12, 2021 /CNW/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada’s particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have rights, including preferred access and pricing, to the resulting alpha-emitting medical isotope. (read more)